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PERENCAT SIRTUIN NOVEL 
ELUSIDASI CARA TINDAKAN DAN LALUAN MOLEKUL DALAM 
TITISAN SEL KANSER KOLOREKTAL 
 
ABSTRAK 
Kanser kolon merupakan salah satu jenis kanser yang paling banyak didapati 
di seluruh dunia. Walaupun kebanyakan pesakit menunjukkan respon yang baik 
terhadap rawatan kimoterapi pada peringkat awal, akan tetapi terdapat banyak kes 
kanser berulang selepas rawatan yang disebabkan oleh kewujudan rintangan terhadap 
rawatan, maka wujudnya keperluan untuk membangunkan agen terapeutik baru 
untuk kanser kolorektal. Sirtuin 1 (SIRT1) dan sirtuin 2 (SIRT2) adalah sasaran 
penting kerana molekul-molekul ini terlibat dalam perkembangan kanser. 
Pengekspresan SIRT1 yang terlampau dilaporkan dalam kanser kolorektal, manakala 
sirtuin 2 (SIRT2) dilaporkan berupaya untuk menindas gen perencat kanser dan 
memainkan peranan penting dalam kelangsungan hidup sel-sel kanser. BZD9L1 
adalah sejenis perencat terhadap molekul-molekul SIRT1 and SIRT2 yang telah 
dilaporkan mempamerkan aktiviti-aktiviti anti-kanser. Projek ini bertujuan untuk 
mengkaji molekul-molekul yang terlibat dalam peranan BZD9L1 merencatkan 
pertumbuhan sel kanser serta regulasi dengan laluan transduksi isyarat yang lain. 
Kesan BZD9L1 terhadap kelangsungan hidup sel, perkembangan, penghijrahan, 
kitaran sel, penuaan selular, apoptosis dan molekul-molekul yang terlibat dalam 
aktiviti-aktiviti ini telah dikaji dalam  HCT116 dan HT-29 sel kanser kolorektal. 
BZD9L1 didapati mengurangkan kelangsungan hidup sel-sel HCT116 dan HT-29,  
tetapi tidak menunjukkan kesan signifikan terhadap kelangsungan sel kolon 
epitelium biasa CCD 841 CoN. Peningkatan dos BZD9L1 didapati mengurangkan 
xvii 
 
percambahan sel dan menghalang penghijrahan dalam kedua-dua jenis sel.  Walau 
bagaimanapun, kompaun ini tidak mempunyai kesan ke atas pengagihan kitaran sel 
dan penuaan selular. Di samping itu, BZD9L1 mengakibatkan pengaktifan PARP 
dan kondensasi kromatin, serta menunjukkan apoptosis dalam kedua-dua sel 
HCT116 dan HT-29. BZD9L1 juga menunjukkan peningkatan pengekspresan faktor 
transkripsi yang terlibat dalam laluan molekular Notch, NF-kB, Myc/Max, ERK dan 
JNK dalam HCT116 tetapi menunjukkan pengurangan pengekspresan faktor 
transkripsi yang berkaitan dengan laluan Wnt, Notch, p53, TGF, NF-kB, Myc/Max, 
HIF dan ERK dalam sel HT-29. Ini  menunjukkan peranan dwifungsi  laluan kanser 
dalam mencapai hasil rawatan yang sama. Kesimpulannya, BZD9L1 mempamerkan 
aktiviti anti-kanser sitotoksik yang menyebabkan kematian sel secara apoptosis 
dalam sel kanser kolorektal.  Oleh itu, penindasan aktiviti SIRT1 dan SIRT2 dengan 
menggunakan BZD9L1 merupakan strategi terapeutik yang berpotensi dalam 
rawatan kanser kolorektal. 
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A NOVEL INHIBITOR OF SIRTUIN: 
ELUCIDATION OF MODE OF ACTION AND MOLECULAR PATHWAY IN 
COLORECTAL CANCER CELL LINE 
 
ABSTRACT 
Colorectal cancer (CRC) is one of the most common types of cancer 
worldwide. Although most patients are responsive to standard chemotherapy 
treatments at the initial stage of diagnosis, many succumb to relapse due to acquired 
chemoresistance, hence driving the need for the development of novel therapeutic 
agents for colorectal cancer. Sirtuin 1 (SIRT1) and sirtuin 2 (SIRT2) are important 
targets as they have been implicated in tumour progression. SIRT1 is overexpressed 
in colorectal cancer, while SIRT2 represses tumour suppressor genes and play key 
roles in cancer cell survival. BZD9L1 is a novel SIRT1 and SIRT2 inhibitor with 
reported anti-cancer activities. This project aimed to investigate the molecular 
players involved in BZD9L1-mediated colorectal cancer cell inhibition as well as its 
regulation of cancer signaling pathways. The effect of BZD9L1 on cell survival, 
proliferation, migration, cell cycle, senescence, apoptosis and the molecular players 
mediating these outcomes were studied in HCT116 and HT-29 colorectal cancer cell 
lines. BZD9L1 reduced the viability of HCT116 and HT-29 cells but displayed non-
significant effect on the cell viability of normal human colon epithelial CCD841 
CoN cells. BZD9L1 significantly reduced cell proliferation and inhibited cell 
migration in increasing doses in both cell lines. However the compound had no effect 
on cell cycle distribution and cellular senescence. In addition, BZD9L1 induced 
cleavage of PARP and chromatin condensation, indicating apoptosis in both cell 
lines. BZD9L1 also upregulated the transcription factors associated with Notch, NF-
xix 
 
kB, Myc/Max, ERK and JNK pathways in HCT116 but downregulated the 
transcription factors related to Wnt, Notch, p53, TGF, NF-kB, Myc/Max, HIF and 
ERK pathways in HT-29 cells, highlighting bifunctional roles of these cancer 
pathways which result in the same treatment outcome. In conclusion, BZD9L1 
exhibited anti-cancer activities as a cytotoxic drug that mediates apoptotic cell death 
in colorectal cancer.  Hence, inhibiting SIRT1 and SIRT2 activities using BZD9L1 
could be a promising therapeutic strategy in the treatment of colorectal cancer. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Introduction to cancer  
Cancer is a disease caused by uncontrolled cell division and proliferation of abnormal 
cells. These mutated cells gain the ability to divide indefinitely with enhanced growth 
rate which often results in the formation of solid cell masses known as tumours. 
Tumours can be categorized as benign (non-cancerous) or malignant (cancerous), with 
the source of tumour origin termed as the primary site. Benign tumours are usually less 
life threatening due to the ease of complete removal through surgery. The case 
however worsens if tumours start to gain the ability to invade into neighboring tissues, 
which often results in the injury of vital organs, hemorrhage, and disruption of 
metabolic activities. The tumour becomes metastatic when cancerous cells detach from 
the primary tumour and migrate to distant organs such as lungs, colon, brain etc. 
through blood vessels and the lymphatic system. 
The incidence of cancer has risen significantly in parallel with the constant 
expansion of world population and increase in aging community. The adoption of 
cancer-causing behaviors such as smoking, physical inactivity, and occupational as 
well as lifestyle exposure to carcinogenic compounds have been shown to encourage 
the risk of developing this deadly disease, particularly in poor and developing 
countries (Jemal et al., 2011, Torre et al., 2015). In addition, International Agency for 
Research on Cancer (IARC) predicts an expected growth of global cancer burden to 
21.7 million new cancer cases by year 2030 with 13 million mortalities simply caused 
by the aging world population (Thun et al., 2010). This rise in global cancer burden is 
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not excluded from developing countries like Malaysia. According to the Malaysia 
Ministry of Health, about 100,000 Malaysians suffer from cancer each year (National 
Cancer Institute, 2016).  
 
1.2 Colorectal Cancer 
Colorectal cancer is the cancer of the colon or the rectum. Colorectal cancer arises 
from abnormal outgrowth of the inner lining of the large intestinal wall known as 
polyps, which if not removed may be malignant (American Cancer Society, 2017). 
Colorectal cancer is ranked as the third most common malignancy in the world 
(GLOBOCAN, 2012; Siegel et al., 2014) and is among the most common cancers in 
developing countries (GLOBOCAN, 2008; Ferlay et al., 2010). According to World 
Health Organization (WHO), colorectal cancer ranks the third most common in men 
(746,000 cases) and second most common in women (614,000 cases) worldwide 
(GLOBOCAN, 2012). During the past 20 years, many Asian countries had witnessed 
the rise in colorectal cancer especially in males (Center et al., 2009). GLOBOCAN 
2012 reported colorectal cancer as the second most common cancer in Malaysia with 
approximately 3000 newly reported cases every year (Veettil et al., 2016). In a country 
with a population of more than 28 million, colorectal cancer is second most common 
among male and third most common among female Malaysians, with a growing 
number of cases every year (Chye and Yahaga, 2004; Omar et al., 2006).  
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1.2.1 Development and staging of colorectal cancer 
Staging refers to a scale of 0 to IV to determine the progression and the event of how 
much the cancer had spread from the primary site. Stage 0 tumours are benign and 
invasion of surrounding tissues were not present, whereas Stage IV tumours are 
malignant and the cancer has metastasized from the primary tumour to distant sites. 
Colorectal tumours are staged based on the evidence of invasion to colon wall and 
spreading to blood vessels and lymphatic systems. Although the tumour size in 
colorectal cancer are less important in terms of treatment outcomes, the cancer 
mortality and prognosis effectiveness have a close correlation to the stage 
advancement (John Hopkins Colon Cancer Center, 2017).  
 Colorectal cancer can be staged based on two staging systems, namely the 
TNM staging system and the Duke’s classification. The TNM staging system was 
developed by the American Joint Committee on Cancer (AJCC) and is the most precise 
and widely used system in cancer diagnostic. Table 1.0 shows the comparison between 
the TNM staging system and Duke’s classification, as adapted from John Hopkins 
Colon Cancer Center (2017) and Figure 1.1 shows the stages of colorectal cancer 
development classified in accordance of American Joint Cancer Committee (Dukes, 
1932; Zatzkin, 2016).  
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Table 1.1 Comparison of TNM staging and Duke’s classification. 
Stages  
 
TNM Classification Duke’s classification 
 T N M 
Stage 0 Tis N0 M0 - 
Stage I T1 N0 M0 A 
T2 N0 M0 B1 
Stage II T3 N0 M0 B2 
T4 N0 M0 B2 
Stage III T1, T2 N1 or N2 M0 C1 
T3, T4 N1 or N2 M0 C2 
Stage IV Any T Any N M1 D 
(Table was adapted from John Hopkins Colon Cancer Center,  2017) 
Key for TNM Staging:  
 
Primary Tumor (T) 
Tis – carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 – tumor invades submucosa 
T2 – tumor invades muscularis propria 
T3 – tumor invades through muscularis propria into subserosa or into 
nonperitonealized pericolic or perirectal tissues 
T4 – tumor directly invades other organs or structures and/or perforates visceral 
peritoneum 
 
Regional Lymph Nodes (N) 
N0 – no regional lymph node metastasis 
N1 – metastasis in one to three regional lymph nodes 
N2 – metastasis in four or more regional lymph nodes 
 
Distant Metastases (M) 
M0 – no distant metastasis 
M1 – distant metastasis  
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Figure 1.1 The stages of colorectal cancer development classified in accordance to 
American Joint Cancer Committee. 
 
(a) Stage 0 (carcinoma in situ): Formation of tumour at the external lining of 
intestinal wall.  
(b) Stage I: Tumours invade through the muscularis mucosae into the submucosa but 
do not reach the muscularis propria. 
(c) Stage II: Divided into Stage II (B1) when tumours invade into the muscularis 
propria and Stage II (B2) when tumuors completely penetrate the smooth muscle 
layer into the serosa.  
(d) Stage III: Tumour penetrates the smooth muscles and invade into the serosa 
following penetration into the lymph nodes.  
(e) Stage IV: Metastasis occurs and tumour cells have travelled to distant organs such 
as lungs, liver and kidneys. 
(Figure is reproduced from Zatzkin, 2016)  
(a) 
(b) 
(c) 
(d) 
(e) 
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1.3 Colorectal cancer therapy 
In cancer therapy, treatment options include physical removal of tumors via surgery 
which is common for early stages. The treatment options for colorectal cancer depends 
largely on the location of the tumour outgrowth, stages of development and patient 
condition. Patients diagnosed with Stage III and Stage IV cancer usually opted for 
surgical removal of tumours, along with radiotherapy and chemotherapy to reduce 
symptoms and remove as much cancerous tissue as possible. The use of chemotherapy 
in early stages of cancer also aims to reduce and curb tumor growth as well as to induce 
tumor shrinkage before surgery, and ultimately reduce the likelihood of developing 
metastasis if the disease progresses (Zheng et al., 2015).  
 
1.3.1 Chemotherapy 
The clinical chemotherapy for colorectal cancer includes the individual use of 
fluorouracil and capecitabine (Xeloda) (Hirsch and Zafar, 2011), where both are anti-
metabolites to cease DNA synthesis and repair, irinotecan (Campto) which is an 
inhibitor to topoisomerase I to interfere with cell proliferation (Saltz, 1998; Eyol et al., 
2016), a combination of folinic acid, fluorouracil and oxaliplatin (FOLFOX) (Yu et 
al., 2009), and a combination of oxaliplatin and capecitabine (XELOX) (Lv et al., 
2012) .  
Although most patients are responsive to standard chemotherapy treatments at 
the initial stage of cancer diagnosis, some exhibit de novo resistance while many 
succumb to relapse due to acquired chemo-resistance; rendering the standard 
chemotherapy regime ineffective. Despite medical advances in colorectal cancer 
treatment, cancer patients undergoing systemic chemotherapy only secure a mere 12.5 % 
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survival chances in the 5-year survival rate, whereas more than 90 % of patients 
experience failure in metastatic cancer treatment due to acquired resistance ( Longley 
and Johnston, 2005; Siegel et al., 2014). Moreover, conventional chemotherapy 
eliminates cancer cells by unselective induction of cell death on actively dividing cells, 
including some actively dividing normal cells which causes severe short-term and 
long-term side effects on the patients (National Cancer Institute, 2015). 
Chemotheraphies may cause nerve damage, fatigue, infertility, drop in platelet count 
and reduction of white blood cells in cancer patients. Patients may also experience hair 
fall, dry and sensitive skin, as well as brittle nails (Cancer Research UK, 2015). In 
addition, standard chemotherapy may increase the risk of developing some other 
cancers such as leukemia as a side effect (Aidan et al., 2013).  
 
1.3.2 Targeted therapy 
Targeted therapies are drugs or antibodies designed to inhibit cancer growth by 
disrupting the molecular pathway essential for cancer growth. Targeted therapies are 
gaining increased recognition, as they have been shown to increase patient overall 
survival rates and keeping cancer at bay (Munagala et al., 2011; Gish et al., 2013; 
Dizon et al., 2016) . As targeted therapies utilize the availability of specific biomarkers 
to target cancer cells,  only patients with cancer expressing these particular biomarkers 
are able to opt for this treatment (Petrelli and Giordano, 2008). 
Several targeted therapy drugs have been developed for treatment of colorectal 
cancer to target main pathways of tumorigenesis either via inhibiting molecules 
responsible for promoting angiogenesis or blocking the tyrosine kinase receptors to 
halt downstream oncogenic signaling pathways. Colorectal cancer targeted therapy 
drugs such as bevacizumab (Fernando and Hurwitz, 2004), cetuximab (Baselga, 2001) 
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and panitumumab (Addeo et al., 2010) are able to target specific cancer cell 
biomarkers thereby killing only cancerous cells but have minimal effects on normal 
non-cancerous cells. Novel treatments targeting molecules or biomolecules 
specifically expressed in cancer may therefore be a better option as compared to 
standard chemotherapy. 
The main pathways involved in the colorectal cancer tumourigenesis potency 
and metastatic potential of colorectal cancer include the vascular endothelial growth 
factor (VEGF) and endothelial growth factor (EGF) pathways (Chee and Sinicrope, 
2010). The VEGF family consists of the potent pro-angiogenic VEGFs (VEGF-A, 
VEGF-B, VEGF-C, VEGF-D and VEGF-E), placental growth factors (PIGFs), and 
vascular endothelial growth factor receptors (VEGFRs) (VEGFR-1, VEGFR-2 and 
VEGFR-3) (Holmes and Zachary, 2005) that play key roles in inducing mitosis and 
regulating permeability of endothelial cells, as well as assisting the dissemination of 
tumour by increasing oxygen and nutrient delivery into the tumour via angiogenesis 
(Moreira et al., 2007; Ranieri et al., 2006). VEGFs (VEGF-A, VEGF-C and VEGF-D) 
and VEGFRs (VEGFR-2, VEGFR-2/3 and VEGFR-3) are also found to induce 
lymphangiogenesis of tumours, which is the promotion of lymphatic vessel growth 
around metastatic tumours to enhance metastasis and lymph flow (Nagahashi et al., 
2010).  
For colorectal cancer treatment, U.S. Food and Drug Administration (FDA) 
approved clinical targeted therapy drugs including bevacizumab, ziv-aflibercept, 
cetuximab, panitumumab and regorafenib. Therapies targeting vessel formation 
through inhibition of VEGF includes bevacizumab (Avastin), ramucirumab (Cyramza), 
and ziv-aflibercept (Zaltrap) (Chee and Sinicrope, 2010; Verdaguer et al., 2016). 
Bevacizumab is a monoclonal antibody developed against the ligand VEGF-A by 
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sequestering the ligand and preventing it from binding to VEGF receptors (VEGFR-2) 
which induces blood vessel formation (Kim et al., 1993; Gordon et al., 2001) . The 
use of this drug is able to increase chemosensitivity and radiosensitivity of colorectal 
tumours (Jain, 2005). Ramucirumab is a monoclonal antibody that binds to the 
extracellular domain of VEGFR-2 receptor, quenching available receptors for VEGF 
ligands. Ziv-aflibercept is a fusion protein comprising the extracellular domains of 
VEGFR-1 and VEGFR-2 fused to human IgG1-Fc which binds to free VEGF ligands, 
hence reducing freely available VEGF ligands (Stewart, 2011). These drugs have been 
approved for use in metastatic colorectal cancer in combination with standard 
chemotherapy drugs. Patients undergone this treatment have been reported to have a 
better overall survival rate, progression-free survival and slower tumour progression 
(Ranieri et al., 2006; Stewart, 2011). 
 The EGFR is a tyrosine kinase that is highly expressed in many cancer types 
including colorectal cancer. This growth-factor-receptor is involved in the alteration 
of cell phenotypes and increases the growth and survival ability of cancer cells (Huang 
and Harari, 1999). Targeted therapy drugs used to target changes to this pathway in 
colorectal cancer are Cetuximab (Erbitux) and Panitumumab (Vectibix). Cetuximab is 
a monoclonal antibody that binds to the extracellular domain of EGFR as a competitive 
inhibitor, and mediates anti-tumour properties by reducing cell proliferation, 
metastasis, angiogenesis, and promotes apoptosis (Goldstein et al., 1995; Baselga, 
2001). Panitumumab is an lgG2 monoclonal antibody that is highly specific to EGFR. 
Similar to Cetuximab, this drug will reduce cell proliferation and induce apoptosis. A 
major drawback of Panitumumab is that the drug is rendered ineffective against 
colorectal cancer with V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) 
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or Neuroblastoma RAS viral oncogene homolog (NRAS) mutation (Weber and 
McCormack, 2008).   
Regorafenib (Stivarga) is another targeted therapy drug used as the last line of 
treatment for metastatic colorectal cancer patients that are chemo-resistant to standard 
chemotherapy (Majithia and Grothey, 2016). Regorafenib functions by inhibiting 
receptor tyrosine kinase (RTK), which in turn blocks tyrosine protein-kinase receptor 
tie2 (VEGRFR-TIE2) and inhibits angiogenesis (Clarke and Hurwitz, 2013; Grothey 
et al., 2013; Lim et al., 2015) . 
 
1.3.3 Limitations in current state of targeted therapy 
Although the discovery of targeted therapy is a major breakthrough in cancer therapy, 
this method is not limitation free. As targeted therapy works by inhibiting specific 
biomarkers essential for cancer progression, the treatment is only effective against 
patients with tumours that contain that particular biomarker. RAS mutations are found 
in 30 % of all cancers, and in 35-45 % of colorectal cancer patients. Colorectal cancer 
patients with mutated KRAS gene were found to have low overall survival rate, and 
poorer or no response toward therapies including combination of targeted therapy 
drugs with standard chemotherapy drugs (Vincenzi et al., 2015). Many targeted 
therapy drugs target the EFGR pathway, and the absence of wild-type KRAS and 
NRAS genes rendered the therapy ineffective. KRAS and NRAS are genes from the 
RAS family that control fate of cells through the cell cycle by relaying signals from 
extracellular to the nucleus. Activation of these mutated genes causes constant 
signaling and promotion of survival genes regardless of blocked EFGR. Thus the 
discovery and development of novel targeted therapy agent is essential.  
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Another limitation is the emergence of circumvention of drug resistance to 
each administered drug. Although most patients showed major effects at the early stage 
of treatment, some patients do not show encouraging responses despite the presence 
of the biomarker target. Many patients failed to achieve complete response or only 
showed partial response, where complete resistance will eventually show after 
approximately a year. This could be contributed by the complexity of oncogenic 
pathway crosstalks in the presence of several mutations, or the failure of drugs to detect 
mutations due to low specificity (Saijo, 2012). Taking targeted therapy agent 
cetuximab as example, mutation at the S492R of EFGR gene in colorectal cancer 
results in resistance to cetuximab, and panitumumab have to be used as an alternative 
to overcome the resistance instead. In multi-cascaded signaling pathways such as the 
VEGF pathway in colorectal cancer, resistance can be achieved when inhibitors (e.g. 
bevacizumab) was used due to the variety of alternative signaling molecules (PIGF 
and fibroblast growth factors, FGF) which can bypass the inhibition to achieve 
proliferation. Furthermore, inhibition of some targets might cause further mutations in 
the tumours. The inhibition of angiogenesis may cause hypoxia in the tumours due to 
activation of hypoxia genes thus leading to promotion of cancer stem cells and 
aggressive proliferation of the tumour cells (Chen and Zhang, 2015). 
In the perspective of research, although more than 800 drugs are under clinical 
development, only a handful amount of 8 % successfully penetrate the market 
(Schilsky et al., 2010). The complexity of cancer regulatory mechanism, different drug 
sensitivity and resistance, lack of biomarkers, conflicting and burdensome regulatory 
requirements are factors contributing to the low success rate (Schilsky et al., 2010).  
 Despite the use of effective strategies in combating cancer by utilizing the high 
specificity of targeted therapies, unpredicted side effects are unavoidable. The 
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common side effects from targeted therapies usually arisen as a result of dysregulation 
of targets of the inhibited molecule in normal tissues (Widakowich et al., 2007). For 
example, EFGR is involved in the proliferation, survival and differentiation 
particularly of the skin (Chen et al., 1987) and gastrointestinal tract; and play an 
important part in the maturation cycle of keratinocyte (Jost et al., 2000, Lynch et al., 
2007). When EFGR is inhibited by anti-EFGR agents such as panitumumab or 
cetuximab, the patient may experience papulopustular eruption (Lynch et al., 2007), 
acne-like rash or folliculitis of the skin (Yano et al., 2003), or even post-chemotherapy 
diarrhea due to the extensive crypt damage in the colon (Playford et al., 2004).  
 
1.4 Epigenetic modification in colorectal cancer 
Cancer is a genetic as well as an epigenetic disease (Sadikovic et al., 2008). In the 
classical view of cancer, the disease has long been hypothesized to be a result of 
accumulated genetic mutations on the oncogenes and tumor-suppressor genes; where 
the activation of cell survival genes and suppression of tumor-suppressor genes would 
cause an uncontrolled cell division and proliferation (Virani et al., 2012). It is only 
until the recent 20 years that the regulation of DNA on epigenetic diseases, including 
cancers are intensively studied (Dawson and Kouzarides, 2012). Epigenetic 
mechanisms are essential in the maintenance of regular function and development of 
genes expressed specifically in different tissue types, and alteration of global 
epigenetic landscape is one of the hallmarks of cancer (Sharma et al., 2010). A body 
of growing evidence has shown that the intrinsic genome stability is influenced by 
multiple interlocking feedback mechanisms, including the DNA methyltransferases 
(DMNTs) and histone-modifying enzymes (such as acetylation, methylation and 
phosphorylation) where perturbations may lead to alterations in gene expression which 
13 
 
ultimately results in cellular transformation and malignant outgrowth (Lund and van 
Lohuizen, 2004; Ropero and Esteller, 2007). Acetylation and deacetylation is the 
addition or removal of an acetyl group to the histone nucleaosome core, which 
corresponds to the activation or deactivation of genes as part of gene regulation. 
This study will focus on the histone acetylation/deacetylation process which 
are highly regulated by two groups of enzymes known as histone acetyl transferases 
(HATs) and histone deacetylases (HDACs) respectively. Among the earliest described 
mechanism for chromatin modification, HDACs are involved in epigenetic regulation 
via the removal of the acetyl- group from ɛ-lysine residues. HDACs are divided into 
four classes (class I, II, III and IV), with high structural and mechanism similarity 
among class I, II and IV (Bosch-Presegue and Vaquero, 2015). Class III HDACs 
comprise of the sirtuin family which was first discovered in yeast Saccharomyces 
cerevisiae. This originally discovered yeast protein silent information regulator 2 
(Sir2p) homolog is a factor involved in the rescue of mating deficiency (Rine et al., 
1979), and the sirtuin family is highly conserved from yeast to human (Landry et al., 
2000) Sir2p was described as a factor in the epigenetic silencing of the mating-type 
loci and nucleolar ribosomal DNA (rDNA) as well as the telomeres via the promotion 
of a heterochromatin-like structure with hypoacetylated histones H3 and H4 N-
terminal tails (Bosch-Presegue and Vaquero, 2011, Bosch-Presegue and Vaquero, 
2015).  
 
1.4.1 Mammalian sirtuins 
The mammalian sirtuins are class III HDACs, which are NAD+-dependent protein 
deacetylases and mono-[ADP-ribosyl] transferases. The mammalian sirtuin family are 
comprised of 7 members (SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 and SIRT7) 
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each varies on catalytic activity, enzyme function and cellular localization (Figure 1.2). 
Each member of the sirtuin family possesses a conserved catalytic domain of 
approximately 250 residues flanked by variable lengths of C-terminal and N-terminal 
sequences which enhance their enzymatic activities and contribute to the different 
specificities and catalytic activities (Pan et al., 2012; Bosch-Presegue and Vaquero, 
2015; Yeong and Oon, 2016).  
 
 
Figure 1.2 Localization and enzymatic activities of mammalian sirtuins. 
SIRT1 (deacetylase) is found in the nucleus but is constantly shuttled in and out of the 
nucleus through the nuclear membrane. SIRT2 (deacetylase) is found mainly in the 
cytoplasm and only transported to the nucleus during G2/M phase of the cell cycle. 
SIRT3 (deacetylase) is mostly present in the mitochondria, and a small amount is also 
found in the nucleolus. SIRT4 (ADP-ribosyltransferase) and SIRT5 (deacetylase, 
demalonylase, desuccinylase) are only present in mitochondria. SIRT6 (deacetylase, 
ADP-ribosyltransferase, demyristoylase, depalmitoylase) is found only in the nucleus 
and SIRT7 (deacetylase) is found only in the nucleolus. (Figure is adapted from Yeong 
and Oon, 2016) 
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The most important and distinct function of mammalian sirtuins is the 
mediation of cellular homeostasis via the detection of changes in the cellular redox 
state caused by stress; which can be either oxidative stress, metabolic stress, or 
genotoxic stress (Rodriguez et al., 2013). By using NAD+ as the enzyme cofactor, 
mammalian sirtuins are able to detect energy fluctuations in the cells due to changes 
in the intracellular redox potential and hence coordinate an appropriate response 
(Bosch-Presegue and Vaquero, 2011). Among many cellular processes modulated by 
sirtuins, the main function of sirtuins can be categorized into 4 processes, such as the 
involvement in chromatin regulation, determination of cellular fate by modulating cell 
cycle arrest or apoptosis in the present of cellular stress, regulation of cellular 
homeostasis, and contribution to developmental and cellular differentiation (Bosch-
Presegue and Vaquero, 2011). 
 
1.4.2 Role of sirtuins in cancer 
As sirtuins are main key players in homeostasis maintenance and longevity, 
deregulation of the family is often linked to the emergence of homeostatic diseases 
such as cardiovascular diseases, neurodegenerative diseases, diabetes, and cancer. 
SIRT1 and SIRT2 possess high potential as a target for cancer therapy and of research 
interest. However, recent studies have reported a contradicting interplay of sirtuins in 
cancer progression. Findings on SIRT1 and SIRT2 in cancer demonstrate interesting 
role as both sirtuins demonstrated as tumor suppressor gene and oncogene. On one 
hand, evidence showed that SIRT1 and SIRT2 are able to protect organisms against 
cancer via curbing oxidative stresses; while other studies suggested the longetivity 
effect of SIRT1 and SIRT2 contributes to cancer progression. The bifunctional roles 
of SIRT1 and SIRT2 are summarized in Figure 1.3. 
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Figure 1.3 The bifunctional role of SIRT1 and SIRT2 in cancer. 
SIRT1/SIRT2 can behave as both tumour suppressor and tumour promoter. 
SIRT1/SIRT2 act as tumour suppressor by increasing genome stability, regulating 
chromatin structure and promoting DNA repair, limiting cellular replicative life span 
and mediates the stress response program. Both SIRT1 and SIRT2 act as a tumour 
promoter by promoting chemoresistance, blocking cell differentiation, promoting cell 
growth, inhibiting senescence and p53-/FOXO3- mediated apoptosis, and promoting 
angiogenesis and vasodilation (Bosch-Presegue and Vaquero, 2011). 
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1.4.2 (a) SIRT1 and cancer 
SIRT1 has become an interesting target for the development of anti-cancer drugs since 
the last decade due to its overexpression in a variety of cancers (Bradbury et al., 2005; 
Hida et al., 2007; Huffman et al., 2007, Zhao et al., 2011) including colorectal cancer 
(Stunkel et al., 2007). Research over the years have found SIRT1 to possess 
bifunctional roles as both tumour promoter and tumour suppressor.  
The role of SIRT1 as tumour suppressor is demonstrated in a study done by 
Firestein et al (2008) where SIRT1 overexpression in mice model with a mutated APC 
(APCmin/+) gene showed reduced colon cancer formation by deacetylating β-catenin 
and promoting cytoplasmic localization of β-catenin. Another study also found that 
SIRT1 sensitizes cells to tumour necrosis factor alpha (TNF-α)-induced apoptosis 
through the deacetylation of RelA/p65 subunit of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) protein (Yeung et al., 2004). Apart from 
mediating pathways stated above, SIRT1 was found to mediate BRCA1 signaling by 
negatively regulating and inhibiting Survivin by deacetylating H3K9 of the protein’s 
promoter region. The absence of Survivin will curb the translation of anti-apoptotic 
proteins (Wang et al., 2008b). SIRT1 in maintaining genome integrity and DNA 
damage repair is another important role as a tumour suppressor. SIRT1 mutant  
(SIRT1-/-) cells were found to form aneuploidy and structural aberrations due to 
abnormal mitosis, and more susceptible to DNA double strand breaks due to impaired 
DNA repair system (Wang et al., 2008a). Apart from the molecular perspectives, in 
vivo studies performed on mice also showed promising results. For instance, transgenic 
mice with overexpressed SIRT1 has been found to undergo a more healthy aging 
process, having a lower probability of carcinomas and sarcomas development and 
being less susceptible to liver cancer (Fan and Luo, 2010). 
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 SIRT1 has been demonstrated as a hallmark of cancer when it is found to play 
critical role in mediating multiple aspects of drug resistance through the reduction of 
drug penetration, suppression of anti-apoptotic mechanisms and promotion of cancer 
stem cells survival (Wang and Chen, 2013). The ability of SIRT1 to deacetylate the 
tumour suppressor gene p53 confirms its role as a tumour promoter through the 
repression of p53-dependent cell cycle arrest and p53-dependent apoptosis in response 
to cellular stress (Vaziri et al., 2001). SIRT1 was also found to cause epigenetic 
silencing of tumour suppressor FOXO family (a subgroup of Forkhead box group of 
transcription factors), resulting in the suppression of DNA damage repair, impaired 
cell cycle control mechanism and loss of FOXO3-mediated apoptosis (Brunet et al., 
2004). Apart from that, SIRT1 was found to deacetylate c-Myc and promotes 
Myc/Max association which in turn stimulates cell proliferation (Mao et al., 2011) and 
drug resistance (Li et al., 2014). Lastly, SIRT1 was found to induce replicative 
immortality of cancer cells by positively regulating the epithelial mesenchymal 
transition (EMT) and hypoxia inducible factors (HIF), hence inducing migration and 
enhanced uptake of nutrients into tumour cells (Dioum et al., 2009; Byles et al., 2012; , 
Chen et al., 2014).  
 
1.4.2 (b) SIRT2 and cancer 
The tumour suppressor role of SIRT2 can be seen in its regulation of the cell cycle. 
SIRT2 is involved in mediating the mitotic checkpoint, where cells are prevented to 
undergo mitosis in the presence of DNA damage (Dryden et al., 2003). It is postulated 
that SIRT2 mediates cell cycle through the regulation of chromatin condensation 
(Inoue et al., 2007). SIRT2 was also shown to play an important role in chromosomal 
segregation as SIRT2-deficient mice were shown to be more prone in developing 
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tumours due to impaired chromosomal segregation (Kim et al., 2011). In addition, 
SIRT2 regulates migration and invasion through downregulation of the Wnt-signalling 
pathway. SIRT2 was also reported to interact with β-catenin, and absence of SIRT2 
was found to enhance cellular migration and invasion through the upregulation of 
matrix metalloproteinase 9 (MMP9) and downregulation of chromodomain-helicase-
DNA-binding protein 1 (CHD1) gene (Nguyen et al., 2014).  
Although SIRT2 is less studied as compared to SIRT1, recent studies showed 
SIRT2 to repress tumour suppressor gene by deacetylating p53 and KRAS gene, 
thereby promoting tumourigenesis and cancer cell survival (Yang et al., 2013). SIRT2 
also represses the FOXO family, and the suppression of FOXO3 by both SIRT1 and 
SIRT2 contributes to the formation of cancer via FOXO3 degradation (Li et al., 2011, 
Wang et al., 2012). 
 
1.5 Commercial sirtuin modulators 
As sirtuin is gaining increasing recognition with its significant role in cancer, drug 
discovery efforts targeting sirtuins is emerging. A number of sirtuin inhibitors 
targeting SIRT1 and/or SIRT2 have been discovered and are currently being developed, 
including  Nicotinamide derivatives, Suramin and its analogs, Splitomicin and its 
analogs, Hydroxynaphthaldehyde derivatives, Thiobarbiturates derivatives, Indole 
derivatives, Indole-isoxazolone derivatives, Tenovin derivatives, Peptidomimetics and 
other compounds with diverse structural cores (Yeong and Oon, 2016). The currently 
available sirtuin modulators, specific targets and type of inhibitors are depicted in 
Table 1.2. 
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Although many sirtuin modulators have been discovered and researched on, further 
development of these modulators are unable to reach clinical trials due to either 
unfavorable physiochemical properties or poor side effects. For instance, compounds 
such as isonicotinamide (Jackson et al., 2003, Schmidt et al., 2004) and suramin 
derivatives (Figg et al., 1994, Gill et al., 1995) were found to exhibit too much toxicity 
and thus proved to be less useful. Other compounds like nicotinamide derivatives, 
splitomicin derivatives (Freitag et al., 2011) and some tenovin derivatives (Lain et al., 
2008) have either poor solubility in water or too lipophilic in nature. Thus, the 
essentiality of discovery of novel sirtuin inhibitor is imminent. 
 
1.6 BZD9L1: A novel SIRT1 and SIRT2 inhibitor 
BZD9L1 is a highly-fluorescent benzimidazole derivative and potent sirtuin inhibitor 
discovered recently in our laboratory. This synthetic compound is known to inhibit 
SIRT1 and SIRT2, with stronger inhibition towards SIRT2. Data from previous work 
has reported BZD9L1 to exhibit a linear progress curve over time which suggests the 
compound is a reversible inhibitor towards SIRT1 and SIRT2.  In an assay performed 
with increasing concentrations of NAD+, BZD9L1 was found to demonstrate 
competitive inhibition, through competition with substrate NAD+ to bind at the same 
active site of SIRT1 and SIRT2 enzyme (Yoon et al., 2015). BZD9L1 was found to 
demonstrate strong anti-proliferative effects across a panel of different tested cancer 
cell lines including leukemia (CCRF-CEM), breast cancer (MDA-MB-468) and 
colorectal cancer (HCT-116) (Yoon et al., 2015), with the strongest anti-proliferative 
activity observed in colorectal cancer.  
 
